VEPO Solutions Appoints Kayla Schultz as Vice President of Sales
VEPO Solutions appoints Kayla Schultz as Vice President of Sales to lead national growth, bringing 10+ years of utility tech sales experience and a customer-focused approach to expand VEPO's software and smart metering services across the U.S.
New York, NY, United States, June 15, 2025 -- VEPO Solutions, a leading provider of utility software solutions and smart metering installation services, proudly announces the appointment of Kayla Schultz as Vice President of Sales. With a strong background in sales and a customer-first approach, Kayla will lead VEPO's national sales strategy as the company continues its rapid growth across the utility sector.
Kayla brings over 10 years of experience in sales strategy, client engagement, and team development within the utility technology and infrastructure industries.
'We are excited to welcome Kayla to VEPO's leadership team,' said Alan Seiler, Managing Partner of VEPO Solutions. 'Her deep understanding of utility operations, combined with a proven ability to lead high-impact sales teams, makes her an excellent fit. Kayla's leadership will play a key role as we continue expanding our innovative software platform and installation services to support utilities nationwide.'
In her new role, Kayla will oversee VEPO's sales initiatives across all markets, focusing on growing utility partnerships, strengthening customer retention, and advancing adoption of VEPO's solutions. These include VEPO's cloud-based work order and asset management software, as well as turnkey smart metering installation services. She will also collaborate closely with internal teams to ensure VEPO's sales strategies align with the company's mission to deliver operational efficiency, compliance support, and measurable value to utilities and municipalities.
'I'm honored to join VEPO Solutions at such an exciting time in its evolution,' said Schultz. 'VEPO is not only modernizing how utilities manage infrastructure and service delivery—it's doing so with a clear focus on customer outcomes and long-term success. I'm excited to lead our sales efforts and support the outstanding work our team is doing across the country.' For more information, please visit www.veposolutions.com.
Contact Info:
Name: Media Relations
Email: Send Email
Organization: VEPO Solutions
Website: https://www.veposolutions.com/
Release ID: 89162344
Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
21 minutes ago
- Wall Street Journal
How the Federal Reserve Fuels Fiscal Profligacy
If Republicans are serious about reducing federal deficit spending, it is important to consider the effect the Federal Reserve has on the nation's budgetary outlook. If the numerical models imposed by the Congressional Budget Office drive fiscal policy, lawmakers also need to understand what they portend for monetary policy. The Fed once was committed to 'normalizing' its balance sheet—shrinking its footprint in credit markets by reducing the size of its portfolio of Treasury debt and mortgage-backed securities. Chairman Jerome Powell noted in a 2019 speech that large-scale asset purchases by the Fed over the previous 10 years had been viewed from the outset as 'extraordinary measures to be unwound, or 'normalized,' when conditions ultimately warranted.'
Yahoo
29 minutes ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Rare earth supply risks: Is Tesla the real target by China?
-- With China granting rare earth export licenses to GM, Ford, and Stellantis (NYSE:STLA) but not to Tesla (NASDAQ:TSLA), questions are mounting over whether Tesla is being deliberately targeted amid ongoing trade tensions and Musk's outspoken foreign policy stance. 'Media reports only indicate GM, F & STLA received licenses. This implies TSLA & RIVN could still be waiting for licenses. It's possible this is the consequence of Musk's aggressive stance on foreign policy & China's aim to support local EV makers,' Wells Fargo wrote, citing expert Dr. Gracelin Baskaran. China controls nearly 100% of global supply for the seven most critical heavy rare earth elements, or REEs, which are essential for electric vehicle motors and other advanced manufacturing. The U.S. auto sector is the largest end-user of these materials, but America's consumption is a fraction of global output—just 6,600 tonnes out of 390,000 tonnes produced last year. Following China's April 4 restrictions, automakers had only 2-3 months of buffer stock, and those reserves are now running low. While the six-month licenses keep operations running for some U.S. automakers, Wells Fargo warns the current arrangement is 'still a band-aid, not a fix,' with supply risks likely to persist for another two to five years as new capacity ramps up outside China. For now, China's selectivity in granting licenses and vigilance over end-use means Tesla—and other OEMs still waiting—could face mounting pressure until global rare earth supply chains diversify. Related articles Rare earth supply risks: Is Tesla the real target by China? 2025 Global Technology Conference: What did we learn? Has AI started replacing junior software developers? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
